Drugs in Context

2.9(top 20%)

impact factor

306(top 50%)

papers

5.4K(top 20%)

citations

36(top 20%)

h-index

3.4(top 10%)

impact factor

491

all documents

6.2K

doc citations

60(top 20%)

g-index

Top Articles

#	Title	Journal	Year	Citations
1	How to manage Pseudomonas aeruginosa infections	Drugs in Context	2018	491
2	A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond	Drugs in Context	2015	253
3	High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease	Drugs in Context	2018	129
4	Antidepressant efficacy and side-effect burden: a quick guide for clinicians	Drugs in Context	2015	125
5	Febrile seizures: an overview	Drugs in Context	2018	125
6	The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy	Drugs in Context	2018	108
7	The journey of remdesivir: from Ebola to COVID-19	Drugs in Context	2020	106
8	Advances in the use of PARP inhibitor therapy for breast cancer	Drugs in Context	2018	101
9	Combination therapy in the treatment of hypertension	Drugs in Context	2018	97
10	Aducanumab: evidence from clinical trial data and controversies	Drugs in Context	2021	96
11	New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance	Drugs in Context	2019	91
12	Menopause hormone therapy: latest developments and clinical practice	Drugs in Context	2019	85
13	Venetoclax: evidence to date and clinical potential	Drugs in Context	2019	83
14	Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges	Drugs in Context	2019	82
15	The race to a COVID-19 vaccine: opportunities and challenges in development and distribution	Drugs in Context	2021	77
16	One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA	Drugs in Context	2014	76
17	Neurological features of COVID-19 and their treatment: a review	Drugs in Context	2020	73
18	Ketamine as treatment for post-traumatic stress disorder: a review	Drugs in Context	2019	72
19	Immunotherapy in renal cell carcinoma: latest evidence and clinical implications	Drugs in Context	2018	63
20	The therapeutic role of minocycline in Parkinson’s disease	Drugs in Context	2019	61
21	Brodalumab in psoriasis: evidence to date and clinical potential	Drugs in Context	2019	61
22	Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib	Drugs in Context	2020	60
23	Palbociclib in metastatic breast cancer: current evidence and real-life data	Drugs in Context	2019	58
24	A review of current treatment strategies for gestational diabetes mellitus	Drugs in Context	2015	55
25	Diagnosis and management of lentigo maligna: a review	Drugs in Context	2015	55
26	Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis	Drugs in Context	2019	55
27	Emollient treatment of atopic dermatitis: latest evidence and clinical considerations	Drugs in Context	2018	52
28	Current treatment in COVID-19 disease: a rapid review	Drugs in Context	2021	51
29	Dermatology: how to manage acne vulgaris	Drugs in Context	2021	50
30	Motion sickness: an overview	Drugs in Context	2019	49
31	The cost of biologics for psoriasis is increasing	Drugs in Context	2014	48
32	Adding ezetimibe to statin therapy: latest evidence and clinical implications	Drugs in Context	2018	44
33	Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors	Drugs in Context	2020	43
34	Gastroesophageal reflux in children: an updated review	Drugs in Context	2019	42
35	Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil	Drugs in Context	2018	41
36	Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents	Drugs in Context	2014	40
37	Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes	Drugs in Context	2014	38
38	Alpha-2 receptor agonists for the treatment of posttraumatic stress disorder	Drugs in Context	2015	38
39	Atopic dermatitis: a review of topical nonsteroid therapy	Drugs in Context	2018	37
40	Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues	Drugs in Context	2019	37
41	Agents to treat BRAF-mutant lung cancer	Drugs in Context	2019	37
42	Metformin in the management of diabetes during pregnancy and lactation	Drugs in Context	2018	36
43	Medication adherence and treatment-resistant hypertension: a review	Drugs in Context	2019	36
44	Treatment of diverticular disease: an update on latest evidence and clinical implications	Drugs in Context	2018	35
45	Chloroquine and hydroxychloroquine in the context of COVID-19	Drugs in Context	2020	35
46	Tinea corporis: an updated review	Drugs in Context	2020	35
47	Guselkumab for the treatment of psoriasis – evidence to date	Drugs in Context	2019	35
48	Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications	Drugs in Context	2018	34
49	Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies	Drugs in Context	2020	34
50	Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies	Drugs in Context	2015	32

Scientometrics

Overviews

Citing Bodies

Drugs in Context

Top Articles